Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients

Journal of Dermatological Treatment

Volumn 22, Issue 4, 2011, Pages 197-205

  Tan, Jerry ^a,b   Gollnick, Harald P M ^c   Loesche, Christian ^d   Ma, Y May ^d   Gold, Linda Stein ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Windsor Clinical Research   (Canada)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d Galderma R and D   (France)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Acne vulgaris; Adapalene BPO; Combination therapy; Efficacy; Synergy

Indexed keywords

ADAPALENE; ADAPALENE PLUS BENZOYL PEROXIDE; BENZOYL PEROXIDE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN DEFECT; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT;

ACNE VULGARIS; ADOLESCENT; ADULT; BENZOYL PEROXIDE; CHILD; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; YOUNG ADULT;

EID: 79851495346     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546631003681094     Document Type: Article

References (42)

1. Hucl T, Gallmeier E, Kern SE. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Cell Cycle. 2007;6:1336-1341. (Pubitemid 47327968)
2. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93-141. (Pubitemid 20019599)
3. SlamonD, PegramM. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28(1 suppl 3): 13-19.
4. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2006;50:3289-3296. (Pubitemid 44527500)
5. Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy. 2003;49:44-48. (Pubitemid 36469796)
6. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003; 49(3 suppl):S200-S210. (Pubitemid 37046534)
7. Campbell JL Jr. A comparative review of the efficacy and tolerability of retinoid-containing combination regimens for the treatment of acne vulgaris. J Drugs Dermatol. 2007; 6(6):625-629.
8. Webster G. Mechanism-based treatment of acne vulgaris: The value of combination therapy. J Drugs Dermatol. 2005; 4(3):281-288.
9. Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol. 2004;3(2):146-154.
10. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne. A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 suppl):S1-S37. (Pubitemid 36791495)
11. Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol. 1975;74(suppl):111-115.
12. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res. 1989;15:447-451. (Pubitemid 20041276)
13. Zouboulis CHC, Derumeaux L, Decroix J, Maclejewska-Udziela B, Cambazards F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498-505.
14. Wolf JE, Kaplan D, Kraus SJ, Loven KH, Rist T, Swingyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: A multicenter, randomized, investigator-blind study. J Am Acad Dermatol. 2003;49(3 suppl):S211-S217. (Pubitemid 37046535)
15. Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: Combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595. (Pubitemid 27446730)
16. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607-615.
17. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59(5):792-800.
18. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: Update on efficacy and safety. Am J Clin Dermatol. 2008; 9(6):369-381.
19. Eady EA, Cove JH, Joanes DN, Cunliffe WJ. Topical antibiotics for the treatment of acne vulgaris: A critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat. 1990;1:215-226. (Pubitemid 20337502)
20. Eady EA. Resistance to antibiotics used in dermatological practice. Br J Dermatol. 1998;139:4-8.
21. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(suppl 52): 8-11. (Pubitemid 28475277)
22. Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18(5):524-526.
23. Andres P, Pernin C, Poncet M. Adapalene-benzoyl perioxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: A randomized, bilateral (split-face), doseassessment study of cutaneous tolerability in healthy participants. Cutis. 2008;81:278-284.
24. Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(9):899-905.
25. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49(3 suppl):S227-S232. (Pubitemid 37046537)
26. Caron D, Sorba V, Clucas A, Verschoore M. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol. 1997;36:S113-S115. (Pubitemid 27265891)
27. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57:791-799. (Pubitemid 47553072)
28. Stein Gold L, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, et al. Adapalene-benzoyl peroxide, a unique fixed dose combination gel for the treatment of acne: A North American, multicenter, randomized, double-blind, controlled, phase III trial in 1,668 patients. Cutis. 2009;84:110-116.
29. Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: A transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189.
30. Thiboutot D, Dréno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;81:81-86.
31. Tan JKL, Balagurusamy M, Fung K, Gupta AK, Thomas DR, Sapra S, et al. The effect of QoL impact and clinical severity on adherence to topical acne treatment. J Cutan Med Surg. 2009;13(4):204-208.
32. Food and Drug Administration. Dermatologic and ophthalmic drugs advisory committee briefing information. Acne global severity scale 2002. [Accessed November 4, 2002.] Available from http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3904B1-03-%20Acne%20Global%20Severity% 20Scale.pdf.
33. Kaidbey KH, Kligman AM, Yoshida H. Effects of intensive application of retinoic acid on human skin. Br J Dermatol. 1975;92:693-701.
34. Fulton JEJr, Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris. J Cutan Pathol. 1974;1(5):181-200.
35. Oh CW, Myung KB. An ultrastructural study of the retention hyperkeratosis of experimentally induced comedones in rabbits: The effects of three comedolytics. J Dermatol. 1996; 23(3):169-180. (Pubitemid 26127574)
36. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
37. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16: 500-506. (Pubitemid 46845393)
38. Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol. 2005;153:1105-1113. (Pubitemid 41779563)
39. Kim J. Review of the innate immune response in acne vulgaris: Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology. 2005;211:193-198. (Pubitemid 41415858)
40. Tanghetti E, Kircik L, Wilson D, Dhawan S. Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. J Drugs Dermatol. 2008; 7(6):534-538.
41. Graham GM, Farrar MD, Cruse-Sawyer JE, Holland KT, Ingham E. Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol. 2004;150:421-428. (Pubitemid 38446295)
42. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: Implications for chronic inflammatory acne. Infect Immun. 1995;63:3158-3165.